metformin has been researched along with Intestinal Neoplasms in 1 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Intestinal Neoplasms: Tumors or cancer of the INTESTINES.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barazeghi, E | 1 |
| Hellman, P | 1 |
| Norlén, O | 1 |
| Westin, G | 1 |
| Stålberg, P | 1 |
1 other study available for metformin and Intestinal Neoplasms
| Article | Year |
|---|---|
EZH2 presents a therapeutic target for neuroendocrine tumors of the small intestine.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Cell Movement; Cell Proliferation; Drug Therapy, Combination; | 2021 |